205 related articles for article (PubMed ID: 11327101)
21. [The role of peroxisome proliferator-activated receptors γ (PPARγ) in obesity and insulin resistance].
Chmielewska-Kassassir M; Woźniak LA; Ogrodniczek P; Wójcik M
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1283-99. PubMed ID: 24379269
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans.
Bar-Tana J
Toxicol Lett; 2001 Mar; 120(1-3):9-19. PubMed ID: 11323157
[TBL] [Abstract][Full Text] [Related]
23. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists.
Mukherjee R; Jow L; Croston GE; Paterniti JR
J Biol Chem; 1997 Mar; 272(12):8071-6. PubMed ID: 9065481
[TBL] [Abstract][Full Text] [Related]
24. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.
De Vos P; Lefebvre AM; Miller SG; Guerre-Millo M; Wong K; Saladin R; Hamann LG; Staels B; Briggs MR; Auwerx J
J Clin Invest; 1996 Aug; 98(4):1004-9. PubMed ID: 8770873
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor gamma-mediated NF-kappa B activation and apoptosis in pre-B cells.
Schlezinger JJ; Jensen BA; Mann KK; Ryu HY; Sherr DH
J Immunol; 2002 Dec; 169(12):6831-41. PubMed ID: 12471115
[TBL] [Abstract][Full Text] [Related]
26. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
27. The nuclear hormone receptor PPARγ as a therapeutic target in major diseases.
Schmidt MV; Brüne B; von Knethen A
ScientificWorldJournal; 2010 Nov; 10():2181-97. PubMed ID: 21057731
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease.
Hsueh WA; Bruemmer D
Hypertension; 2004 Feb; 43(2):297-305. PubMed ID: 14732733
[TBL] [Abstract][Full Text] [Related]
29. [Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism].
Andrééva-Gatéva P
Ann Biol Clin (Paris); 2003; 61(3):295-303. PubMed ID: 12805006
[TBL] [Abstract][Full Text] [Related]
30. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice.
DeLuca JG; Doebber TW; Kelly LJ; Kemp RK; Molon-Noblot S; Sahoo SP; Ventre J; Wu MS; Peters JM; Gonzalez FJ; Moller DE
Mol Pharmacol; 2000 Sep; 58(3):470-6. PubMed ID: 10953038
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Schupp M; Janke J; Clasen R; Unger T; Kintscher U
Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
[TBL] [Abstract][Full Text] [Related]
32. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
[TBL] [Abstract][Full Text] [Related]
33. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo.
Cesario RM; Klausing K; Razzaghi H; Crombie D; Rungta D; Heyman RA; Lala DS
Mol Endocrinol; 2001 Aug; 15(8):1360-9. PubMed ID: 11463859
[TBL] [Abstract][Full Text] [Related]
34. Retinoid X receptor expression in skeletal muscle of nondiabetic, obese and type 2 diabetic individuals.
Codner E; Loviscach M; Ciaraldi TP; Rehman N; Carter L; Mudaliar S; Henry RR
Metabolism; 2001 Jul; 50(7):830-4. PubMed ID: 11436190
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
Chinetti G; Fruchart JC; Staels B
Inflamm Res; 2000 Oct; 49(10):497-505. PubMed ID: 11089900
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
Duran-Sandoval D; Thomas AC; Bailleul B; Fruchart JC; Staels B
Med Sci (Paris); 2003; 19(8-9):819-25. PubMed ID: 14593612
[TBL] [Abstract][Full Text] [Related]
37. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.
Leesnitzer LM; Parks DJ; Bledsoe RK; Cobb JE; Collins JL; Consler TG; Davis RG; Hull-Ryde EA; Lenhard JM; Patel L; Plunket KD; Shenk JL; Stimmel JB; Therapontos C; Willson TM; Blanchard SG
Biochemistry; 2002 May; 41(21):6640-50. PubMed ID: 12022867
[TBL] [Abstract][Full Text] [Related]
38. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
Tsujie M; Nakamori S; Okami J; Hayashi N; Hiraoka N; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Exp Cell Res; 2003 Sep; 289(1):143-51. PubMed ID: 12941612
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Marx N; Duez H; Fruchart JC; Staels B
Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
[TBL] [Abstract][Full Text] [Related]
40. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
Larsen TM; Toubro S; Astrup A
Int J Obes Relat Metab Disord; 2003 Feb; 27(2):147-61. PubMed ID: 12586994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
